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Abstract
Introduction Hepatocellular carcinoma (HCC) is a major
cause of cancer worldwide. The vast majority of cases
occur in individuals with a chronic HBVor HCV infection.
In addition, a number of metabolic diseases of the liver are
associated with the development of HCC.
Pathophysiologic Mechanisms The mechanisms responsi-
ble for the progression of the metabolic liver disease and
HCC differ from those associated with viral liver disease.
Conclusions The purpose of this report is to describe the
mechanisms responsible for the disease progression and
HCC in case of metabolic liver disease. A secondary goal is
to identify the frequency of HCC development in the
disorders described.
Keywords Hepatocellular carcinoma.Cancer.NAFLD.
NASH
Introduction
Hepatocellular carcinoma [1–6] is a major cause of cancer
and cancer-related deaths worldwide. The vast majority of
cases are a consequence of a preexisting chronic viral
infection due to either hepatitis B with or without
associated hepatitis D or hepatitis C [7–9].
The number of cases directly related to hepatitis B
(HBV) infection has remained stable worldwide with most
of the cases of HBV-associated HCC occurring in Southeast
Asia and Sub-Saharan Africa [7–9].
In contrast, the number of cases of HCV has increased
and is expected to steadily increase over the next 20–
30 years as a result of the continuing problem of HCV
infection and disease chronicity [4, 10–13].
The majority of cases of HCV-related HCC occur in
Europe and the Americas. The number of HCC cases that
occur, independent of a preexisting viral infection, is
increasing worldwide as a consequence of the global
increase in individuals manifesting one or more of the
components of the metabolic syndrome that include obesity,
coronary artery disease, hyperlipidemia, type 2 diabetes
mellitus, gout, sleep apnea, and nonalcoholic fatty liver
diseases (NAFLD) or nonalcoholic steatohepatitis (NASH)
[14–23].
In addition, a much smaller yet substantial number of
cases are a consequence of chronic alcohol-associated
cirrhosis or one or a large number of inherited metabolic
liver diseases, the most common of which are alpha-1
antitrysin deficiency, hemochromatosis, Wilson’s disease,
and type 1 tyrosenemia [24].
Finally, the few residual cases of non-viral HCC that
have been ascribed to environmental exposures to include
aflatoxin in contaminated grains, tobacco use, oral contra-
ceptives, and use of anabolic steroids.
Pathophysiologic Mechanisms
The underlying mechanisms responsible for these non-viral-
associated HCC are in general a consequence of an epigenetic
event that persists and disrupts the normal cell cycle that
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or a genetic polymorphism that enhances the risk for HCC
development [24].
Considerable data exist for the former epigenetic factor
hypothesis while relatively little and variable data exist for
the presence of an intrinsic genetic mutation leading to the
development of HCC other than those associated with well-
recognized metabolic liver diseases.
Regardless of the specific epigenetic mechanisms in-
volved, enhanced oncogene transcription or its promotion,
reduced degradation of a cyclin, DNA, RNA on regulatory
protein occurring as a result of hyper- or hypo-methylation of
DNA and/or RNA, free radical induced per oxidation or the
presence of either reactive oxygen or nitrosyl compounds,
occurring as a result of oxidative stress.
The vast majority of non-viral-associated HCC manifest
biochemical evidence of insulin resistance and/or deregula-
tion of a growth factor (including insulin) [25, 26].
As a direct consequence of these various mechanisms
leading to the development in HCC, it is not surprising that
HCCs are heterogeneous in their growth rates, degree of
cellular differentiation (morphology), cellular origin, and
potential for metastasis.
Representative Disease Examples
Alcoholic Liver Disease
It is estimated that 15–20% of alcoholics with cirrhosis
develop HCC at a rate of 3–4%/year. In rare cases,
occurring in the absence of cirrhosis either an unrecognized
low-grade chronic hepatitis C or an occult case of HBV
infection can be identified and manifested by H B core
antibody positivity.
The principal pathophysiologic mechanism leading to
HCC in chronic alcoholics, however, is an oxidative
stress induced within the liver as a direct consequence of
the metabolism of ethanol, its first metabolic product
acetaldehyde, and possibly acetate by mitochondria and
the rich endoplasmic recticulum found in the hepatic
cytosil [27, 28].
The resultant loss of ATP production and cellular injury
occurring as a result of membrane phospholipid and protein
oxidation, protein carbonyl formation, and the production
of 1-hydroxyethanol radicals as well as other alkyl free
radicals leads to altered cell signaling mechanisms, tran-
scription, and translation errors that ultimately result in the
development of HCC.
The consequences of ethanol related nutritional pertur-
bations that include folate deficiency, pyridoxylphosphate
deficiency, and a diet rich in carbohydrates and lipids at the
expense of protein are additional factors that contribute to
the enhanced expression of protocongenes and oncogenes
and the risk of HCC development [29–35].
NAFLD and NASH
The current worldwide epidemic of NAFLD occurring in
children as well as adults and in lean as well as obese
individuals has resulted in a remarkable increase in the
number of cases of HCC occurring in the Western World
and more opulent numbers of the Third World who have no
evidence for either current or past HBV and/or HCV
infection [16–20].
Currently, NAFLD is considered a benign condition that
can progress to NASH in approximately 20% of cases. In
turn, 20% of NASH cases are thought to progress to
cirrhosis. HCC can develop in individuals with NASH
combined with cirrhosis and also albeit less often in cases
with NASH occurring in the absence of cirrhosis. The
actual rate of HCC development in NASH-associated
cirrhosis is estimated to be similar to that occurring in
alcoholics with cirrhosis (3–4%/year). There are no current
estimates of the rate of HCC development in cases of
NASH without cirrhosis but increasingly, such cases are
being recognized.
The pathophysiologic mechanisms leading to HCC in
NASH and NASH plus cirrhosis appear to mirror the events
occurring in alcoholic liver disease enhanced further by the
presence of insulin resistance.
Insulin resistance is known to be associated with a
reduction of tyrosine, phosphorytation in many different
cells and organs. As a result, alternate cellular pathways
affecting cell proliferation and differentiation are upregu-
lated. The combination of the upregulation of proteins
responsible for cellular proliferation and differentiation
coupled with the net oxidation stress induced by the hepatic
metabolism of triglycerides is a potent driving force for the
development of HCC.
Hepatic Disorders of Iron and Copper Metabolism
Cases of both HFE and non-HFE associated determined
hepatic iron overload (hemochromatosis) as well as cases of
excessive hepatic copper retention as occurs in Wilson’s
disease result in the development of cirrhosis, and in 7.5–
30% of these cirrhotic cases, a HCC develops. Rare cases
of non-cirrhotic HCC have been reported in both forms of
hepatic metal overload [36–42].
The pathophysiology of these disorders is characterized
by mitochondrial dysfunction with the production of
reactive oxygen and reactive nitrozyl species that charac-
terize oxidative stress. The resultant disruption of cell
cycling in these two disorders is characterized by enhanced
cellular replication as well as an increased apoptosis rate.
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individuals with either hepatic iron or copper overload and
may further enhance the risk of HCC occurring as a
consequence of the more obvious oxidation stress present in
these two disorders. Iron reduction therapy reduces the
prevalence of cirrhosis and, as a result, HCC in cases of
hemochromatosis. Most cases of Wilson’s disease are
recognized clinically only after cirrhosis has developed,
but it is likely that copper reduction therapy in precirrhotic
individuals with Wilson’s disease identified by means of
family screening may lead to a reduced rate of HCC
development as well.
Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is an autosomal recessive
disorder resulting in the expression of a defective alpha-1
antitrypsin protein as a consequence of the presence of an
abnormal allele. The abnormal alleles currently recog-
nized in cases of alpha antitrypsin deficiency include, Z,
S, F, and null alleles. Individuals who are homozygous
for an abnormal allele or are a compound heterozysate
having two different abnormal alleles manifest the clinical
disorder.
HCC is common in children with alpha-1 antitrypsin
deficiency and cirrhosis as well as in adults who are 50–
60 years of age. In the adult cases of alpha-1 antitrypsin
with cirrhosis, HCC is reported to occur in 31–67% of
cases [43–45].
The hepatic endoplasmic reticulum and mitochondrion
in individuals with alpha-1 antitrypsin deficiency demon-
strate morphologic and biochemical abnormalities. As a
result, the sum of the many different cellular injuries
associated with oxidative stress associated with mitochon-
drial injury is thought to be the driving force for HCC
development in cases of alpha-1 antitrypsin deficiency.
Tyrosinemia Type 1 or Hepatorenal Tyrosenemia
Tyrosenemia type 1 is an autosomal recessive disorder due
to deficiency of Fummaryl acetoacetate hydrolase which
results in an accumulation of Fummaryl acetonatate and
malyl aceto acetate [46].
Type 1 tyrosinemia has a worldwide prevalence of 1/
100,000 live births but occurs at an increased rate as high as
½,000 live births in specific geographic locations [47].
Apoptosis characterizes the histological appearance of the
liver affected by type 1 tyrosinemia [48]. The apoptosis
signal appears to be fumaryl acetoacetate. Both fumaryla-
cetoacetate and malyl acetoacetate are alkylating agents that
induce DNA and RNA mutagenesis. As is the case in all of
all of the preceding diseases, a prominent oxidative stress
occurs in tyrosinemia as a consequence of the metabolism
of malylacetone, fummarylacetone, succinylacetate, and
succinylacetone.
Summary and Conclusions
The epigenetic and resultant genetic alterations produced as
a consequence of an excessive oxidative stress characterizes
the diseases of metabolism that are associated with the
development cirrhosis and ultimately HCC.
These metabolic alterations result in gene over- and
underexpression enhanced proliferation, reduced apoptosis,
proto-oncogene, oncogene over expression, and reduced
levels of cycling dependent kinase inhibitors.
The specific alteration that is most evident in a given
disease associated with HCC development varies with and
across diseases making a more specific description of the
pathogenesis of HCC any difficult.
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